Patterns and persistence of SARS-CoV-2 IgG antibodies in Chicago to monitor COVID-19 exposure
Authors:
- Alexis R. DemonbreunADAlexis R. Demonbreun
- Thomas W. McDadeTMThomas W. McDade
- Lauren A. VaughtLVLauren A. Vaught
- Nina L. ReiserNRNina L. Reiser
- Elena BogdanovicEBElena Bogdanovic
- Matthew P. VelezMVMatthew P. Velez
- Ryan R. HsiehRHRyan R. Hsieh
- Lacy M. SimonsLSLacy M. Simons
- Rana SaberRSRana Saber
- Daniel T. RyanDRDaniel T. Ryan
- Michael G. IsonMIMichael G. Ison
Open Access
- 10 May 2021
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (9)
Abstract
BACKGROUND: Estimates of seroprevalence to SARS-CoV-2 vary widely and may influence vaccination response. We ascertained IgG levels across a single US metropolitan site, Chicago, from June 2020 through December 2020. METHODS: Participants ( n = 7935) were recruited through electronic advertising and received materials for a self-sampled dried-blood spot assay through the mail or a minimal contact in-person method. IgG against the receptor-binding domain of SARS-CoV-2 was measured using an established highly sensitive and highly specific assay. RESULTS: Overall seroprevalence was 17.9%, with no significant difference between method of contact. Only 2.5% of participants reported having had a diagnosis of COVID-19 based on virus detection, consistent with a 7-fold greater exposure to SARS-CoV-2 measured by serology than that detected by viral testing. The range of IgG level observed in seropositive participants from this community survey overlapped with the range of IgG levels associated with COVID-19 cases having a documented positive PCR test. From a subset of those who participated in repeat testing, half of seropositive individuals retained detectable antibodies for 3 to 4 months. CONCLUSION: Quantitative IgG measurements with a highly specific and sensitive assay indicated more widespread exposure to SARS-CoV-2 than observed by viral testing. The range of IgG concentrations produced from these asymptomatic exposures was similar to IgG levels occurring after documented nonhospitalized COVID-19, which were considerably lower than those produced from hospitalized COVID-19 cases. The differing ranges of IgG response, coupled with the rate of decay of antibodies, may influence response to subsequent viral exposure and vaccine. Funding: National Science Foundation grant 2035114, NIH grant 3UL1TR001422-06S4, NIH National Center for Advancing Translational Sciences grants UL1 TR001422 and UL1 TR002389, Dixon Family Foundation, Northwestern University Cancer Center (NIH grant P30 CA060553), and Walder Foundation’s Chicago Coronavirus Assessment Network.Keywords
All Related Versions
Funding Information
- National Institutes of Health (3UL1TR001422-06S4)
This publication has 21 references indexed in Scilit:
- Humoral Immune Response to SARS-CoV-2 in IcelandNew England Journal of Medicine, 2020
- Kinetics of viral load and antibody response in relation to COVID-19 severityJournal of Clinical Investigation, 2020
- SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient bloodNature Communications, 2020
- High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, MassachusettsThe Journal of Infectious Diseases, 2020
- Prevalence of SARS-CoV-2 Antibodies in Health Care Personnel in the New York City AreaJAMA, 2020
- High SARS-CoV-2 antibody prevalence among healthcare workers exposed to COVID-19 patientsJournal of Infection, 2020
- High seroprevalence for SARS-CoV-2 among household members of essential workers detected using a dried blood spot assayPLOS ONE, 2020
- Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based studyThe Lancet, 2020
- Antibody tests for identification of current and past infection with SARS-CoV-2Cochrane Database of Systematic Reviews, 2020
- A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoVScience, 2020